• PRODUCTS
    • Assay Kit Platform & Formats
    • Reporter Assays By Receptor
    • Growth Factor Assays
    • Toxicology Kits
      • In Vitro Hepatotoxicity Assay Kit & Screening Services
      • Assay Kits & Services for Gene Expression Profiling
      • Human P-Glycoprotein / MDR1 Drug Interaction Assay Kit & Screening Services
    • Environmental Monitoring Assays
    • Animal Model Assays
    • INDIGlo Luciferase Detection Reagent
    • Live Cell Multiplex
  • SERVICES
    • Reporter Assay Services
    • Nuclear Receptor Profiling & Panels
    • Custom Assay Development
    • Environmental Testing Assays
    • Toxicology in The Drug Discovery and Development Process
  • RESOURCES
    • Nuclear Receptor Overview
    • Disease State Targets
      • Overview
      • Anemia & Kidney Disease
      • Autoimmune Disease & Inflammation
      • Cancer
      • Cardiovascular Disease
      • Diabetes
      • Endocrinology
      • NAFLD/NASH
      • Obesity
    • Articles, Blogs, and Posters
      • New Research Publications
      • Scientific Whitepapers from INDIGO
      • Scientific Posters from INDIGO
      • BLOG
    • Product Literature
      • INDIGO Technical Manuals
      • Product Material Safety Data Sheets
      • upcyte® Hepatocytes
    • FAQ
  • ABOUT
    • About INDIGO
    • Why INDIGO
    • Key Personnel
      • Board of Directors & Advisors
      • Management
    • Employment
    • INDIGO Press Releases
    • INDIGO in the News
  • CONTACT US
    • Contact INDIGO
    • Request a Quote
    • Ordering & Distributors
Search site...

± α β γ δ Δ ε ζ κ ω ö ® ™ µ

  • PRODUCTS
    • Assay Kit Platform & Formats
    • Reporter Assays By Receptor
    • Growth Factor Assays
    • Toxicology Kits
      • In Vitro Hepatotoxicity Assay Kit & Screening Services
      • Assay Kits & Services for Gene Expression Profiling
      • Human P-Glycoprotein / MDR1 Drug Interaction Assay Kit & Screening Services
    • Environmental Monitoring Assays
    • Animal Model Assays
    • INDIGlo Luciferase Detection Reagent
    • Live Cell Multiplex
  • SERVICES
    • Reporter Assay Services
    • Nuclear Receptor Profiling & Panels
    • Custom Assay Development
    • Environmental Testing Assays
    • Toxicology in The Drug Discovery and Development Process
  • RESOURCES
    • Nuclear Receptor Overview
    • Disease State Targets
      • Overview
      • Anemia & Kidney Disease
      • Autoimmune Disease & Inflammation
      • Cancer
      • Cardiovascular Disease
      • Diabetes
      • Endocrinology
      • NAFLD/NASH
      • Obesity
    • Articles, Blogs, and Posters
      • New Research Publications
      • Scientific Whitepapers from INDIGO
      • Scientific Posters from INDIGO
      • BLOG
    • Product Literature
      • INDIGO Technical Manuals
      • Product Material Safety Data Sheets
      • upcyte® Hepatocytes
    • FAQ
  • ABOUT
    • About INDIGO
    • Why INDIGO
    • Key Personnel
      • Board of Directors & Advisors
      • Management
    • Employment
    • INDIGO Press Releases
    • INDIGO in the News
  • CONTACT US
    • Contact INDIGO
    • Request a Quote
    • Ordering & Distributors
Print Friendly, PDF & Email

Reporter Assays By Receptor

INDIGO Biosciences’ cell-based, luciferase reporter assay kits feature receptor-specific reporter cells prepared using our unique CryoMite™ process which typically present greater than 95% cell viability and are ready for immediate use. INDIGO’s assay kits are engineered to provide optimal assay sensitivity and dynamic range when quantifying receptor activity. All assays are available as all-inclusive kits and  as contract screening services.

  • Receptor Assays
  • Ortholog Assays
  • Panel Kits
  • Toxicology Assays
Androgen Receptor (AR; NR3C4)
Aryl Hydrocarbon Receptor (AhR)
Activator Protein-1 (AP-1)
Cannabinoid Type 1 Receptor (CB1R, CNR1)
Constitutive Androstane Receptor-1 (CAR-1; NR1I3i1)Constitutive Androstane Receptor-2 (CAR-2; NR1I3i2)Constitutive Androstane Receptor-3 (CAR-3; NR1I3i3)
Epidermal Growth Factor Receptor 1 (EGFR1)
Erythropoietin Receptor (EPOR)
Estrogen Receptor Alpha (ERα; NR3A1)Estrogen Receptor Beta (ERβ; NR3A2)
Estrogen-related Receptor Alpha (ERRα; NR3B1)Estrogen-related Receptor Beta (ERRβ; NR3B2)Estrogen-related Receptor Gamma (ERRγ; NR3B3)
Fibroblast Growth Factor Receptor 1&2 (FGFR1/2)
Fibroblast Growth Factor Receptor 1c and β-Klotho (FGFR/β-Klotho)
Farnesoid X Receptor (FXR; NR1H4)
Glucocorticoid Receptor (GR; NR3C1)
Growth Hormone Receptor (GHR)
Liver Receptor Homolog-1 (LRH-1; NR5A2)
Liver X Receptor Alpha (LXRα; NR1H3)Liver X Receptor Beta (LXRβ; NR1H2)
Mineralocorticoid Receptor (MR; NR3C2)
Nuclear Factor kappa-light-chain enhancer of activated B cells (NF-kB)
Nuclear Factor of Activated T cells (NFAT)
Nuclear Factor (erythroid-derived 2)-like 2 (Nrf2)
Human Tumor Protein p53 (p53)
Platelet-Derived Growth Factor Receptor α and β (PDGFRα/β)
Peroxisome Proliferator-Activated Receptor Alpha (PPARα; NR1C1)Peroxisome Proliferator-Activated Receptor Beta/Delta (PPARβ/δ; NR1C2)Peroxisome Proliferator-Activated Receptor Gamma (PPARγ; NR1C3)
Pregnane X Receptor (PXR; NR1I2)
Progesterone Receptor (PGR; NR3C3)
Retinoic Acid Receptor Alpha (RARα; NR1B1)Retinoic Acid Receptor Beta (RARβ; NR1B2)Retinoic Acid Receptor Gamma (RARγ; NR1B3)
RAR-related Orphan Receptor Alpha (RORα; NR1F1)RAR-related Orphan Receptor Gamma (RORγ; NR1F3)
Retinoid X Receptor Alpha (RXRα; NR2B1)Retinoid X Receptor Beta (RXRβ; NR2B2)Retinoid X Receptor Gamma (RXRγ; NR2B3)
TEAD4/YAP (Hippo Pathway)
Thrombopoietin Receptor (TPOR)
Thyroid Hormone Receptor Alpha (TRα; NR1A1)Thyroid Hormone Receptor Beta (TRβ; NR1A2)
Transforming Human Growth Factor Beta Receptor I/II (TGFβR)
Human G Protein-Coupled Bile Acid Receptor (TGR5; GPBAR1)
Tropomyosin Receptor Kinase A (TrkA; NTRK1)Tropomyosin Receptor Kinase B (TrkB; NTRK2)Tropomyosin Receptor Kinase C (TrkC; NTRK3)
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
Vitamin D Receptor (VDR; NR1I1)

Many labs are interested in cross-species comparisons, especially contrasting human nuclear receptor activity to common laboratory animals. Determining a drug candidate’s cross-activity with human xenobiotic-sensing receptors provides important early indications of that drug’s potential for downstream drug-drug interactions. With animal studies required by the FDA, selecting the animal model that provides the most representative human-surrogate is critical to assessing a potential drug’s likelihood of unwanted effects. Cell-based assay models are crucial to help make this determination prior to entering ADMET studies.

With more than 30 ortholog assays - including rat, mouse, dog, monkey, and zebrafish - available as kits and/or services, and others available for custom development, INDIGO helps researchers screen the right animal, before trial.

Product FamilyCyn MonkeyDogMouseRabbitRatZebrafish
Androgen ReceptorrARzAR
Aryl Hydrocarbon Receptor mAhRrAhRzAhR
Constitutive Androstane ReceptormCAR
Estrogen Receptor AlpharERαzERα
Estrogen Receptor BetarERβ
Farnesoid X ReceptorcFXRdFXRmFXRrFXR
Glucocortioid ReceptormGRrGRzGR
Liver X Receptor AlphamLXRαrLXRα
Liver X Receptor BetamLXRβrLXRβ
Peroxisome Proliferator-Activated Receptor AlphacPPARαdPPARαmPPARαrPPARα
Peroxisome Proliferator-Activated Receptor Beta/DeltacPPARβ/δdPPARβ/δmPPARβ/δrPPARβ/δ
Peroxisome Proliferator-Activated Receptor GammacPPARγm/rPPARγm/rPPARγzPPARγ
Pregnane X ReceptorcPXRdPXRmPXRrPXR
Progesterone ReceptorcPGRrbPGRrPGR
Retinoic Acid Receptor AlphazRARαa
RAR-related Orphan Receptor GammamRORγrRORγ
Thyroid Hormone Receptor BetazTRβ

INDIGO’s nuclear receptor reporter assay panels contain all materials needed to perform either 32 or 48 assays for each receptor included. PPAR, RAR, and RXR Panels are available in a 3x32-well format; ER, LXR, and TR Panels are in a 2x48-well format, all designed to fully utilize a single 96-well plate. All reagents are supplied with sufficient extra volume to accommodate the needs of performing separate groups of assays. When screening a smaller number of compounds against all variants of a receptor, INDIGO’s Assay Panel kits allow researchers to save time, cost, and risk by screening against multiple receptors in one easy-to-use kit.

Estrogen Receptor PANEL (ERα; ERβ)Liver X Receptor PANEL (LXRα; LXRβ)Peroxisome Proliferator-Activated Receptor PANEL (PPARα; PPARβ/δ; PPARγ)
Retinoic Acid Receptor PANEL (RARα; RARβ; RARγ)Retinoid X Receptor PANEL (RXRα; RXRβ; RXRγ)Thyroid Hormone Receptor PANEL (TRα; TRβ)

In Vitro Screening for Drug-Induced Hepatotoxicity using upcyte® Hepatocytes

The emergence of liver toxicity is major reason for the termination of clinical drug trials, as well as post-market withdrawal of approved drugs. The assay kit for in vitro screening for drug-induced hepatotoxicity allows researchers to rapidly identify those compounds that induce liver toxicity. The kit utilizes upcyte® hepatocytes, prepared using our proprietary CryoMiteTM process, which yields high viability post-thaw and provides the convenience of immediately dispensing cells into assay plates. This all-inclusive assay kit allows users to bring processes previously available only as contract screening services into their own labs. Learn more.

Human MDR1 / P-Glycoprotein Drug Interaction Assay

Determining if a drug candidate will have incidental interactions with P-Glycoprotein (P-gp, aka MDR-1, or ABCB1) is an important component of the safety assessment process. A drug that is either a substrate or inhibitor of MDR1 transporter activity can significantly alter the rate of absorption, distribution, metabolic conversion, and eventual excretion of co-administered drugs, thereby shifting their therapeutic effects and toxicologic profiles. Because of this, assessing a new drug's potency as an interactor with P-gp, and thus its potential liability for inducing downstream drug-drug interactions, is mandated by the FDA. Our all-inclusive assay kit for the assessment of MDR1 drug interaction allows users to rapidly assess drug candidates as either inhibitors, substrates, or non-substrates of P-gp, and make critical decisions about potential drug candidates with confidence. Learn more.

Expression Profiling of Clinically Relevant CYPs Utilizing upcyte® Hepatocytes

Assessing drug-induced changes in the expression of Cytochrome P450 (CYP) genes provides a reliable predictive indicator of altered metabolic activity in vivo. It is estimated that CYPs are involved in 70% to 80% of drugs currently on the market, making understanding their metabolic actions crucial to the drug development process. Our gene expression assay kit provides optimized reagents for the culturing and treatment of upcyte® hepatocytes to assess drug-induced changes in the expression of seven clinically relevant CYPs: CYP3A4, CYP1A1, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2E1. Learn more.

Request a Quote

Search

Search site...
Click to Insert Symbols in Search

α β γ δ Δ ε ζ κ ® ™ µ

Want More Information?

Resource Quick Links

  • Technical Manuals & Product Listing
  • Safety Data Sheets
  • Sample Study Report
  • Study Work Order Form

3006 Research Drive, Suite A1, State College, PA, USA 16801

+1 (814) 234-1919

  • Terms Conditions
  • Privacy Policy
  • Product Policies
  • Limited Use Disclosure

© 2022 INDIGO Biosciences, Inc. All Rights Reserved